Cytotoxicity and anti-inflammatory activity of cyclosporine a loaded plga nanoparticles for ocular use

Pharmazie

Volumn 69, Issue 1, 2014, Pages 32-37

  Hermans, K ^a   Van Den Plas, D ^a   Schreurs, E ^a   Weyenberg, W ^a   Ludwig, A ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; CARNITINE; CONCANAVALIN A; CYCLOSPORIN A; INTERLEUKIN 2; NANOPARTICLE; POLYGLACTIN; TREHALOSE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY TEST; DISPERSION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG FORMULATION; DRUG RELEASE; EPITHELIUM CELL; EVAPORATION; FREEZE DRYING; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL LINE; NANOEMULSION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARTICLE SIZE; PHYSICAL CHEMISTRY; PROTEIN EXPRESSION; SURFACE PROPERTY; T LYMPHOCYTE; ZETA POTENTIAL;

CARCINOGENS; CELL SURVIVAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOSPORINE; ELECTROCHEMISTRY; EXCIPIENTS; FREEZE DRYING; HUMANS; INTERLEUKIN-2; JURKAT CELLS; LACTIC ACID; MAGNETIC RESONANCE SPECTROSCOPY; NANOPARTICLES; OPHTHALMIC SOLUTIONS; PARTICLE SIZE; POLYGLYCOLIC ACID; PROTECTIVE AGENTS; SOLUBILITY;

EID: 84893053770     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2014.2206     Document Type: Article

References (23)

1. Aksungur P, Demirbilek M, Denkbas EB, Vandervoort J, Ludwig A, Ünlu N (2011) Development and characterization of cyclosporine A loaded nanoparticles for ocular delivery: cellular toxicity, uptake, and kinetic studies. J Control Release 151: 286-294.
2. Baldari CT, MacChia G, Heguy A, Melli M, Telford JL (1991) Cyclosporin A blocks calcium-dependent pathways of gene activation. J Biol Chem 266: 19103-19108. (Pubitemid 21908198)
3. ChenW, Zhang X, Liu M, Zhang J, Ye Y, Lin Y, Luyckx J, Qu J (2009) Trehalose protects against ocular surface disorders in experimental murine dry eye through suppression of apoptosis. Exp Eye Res 89: 311-318.
4. Corrales RM, Luo L, Chang EY, Pflugfelder SC (2008) Effects of osmoprotectants on hyperosmolar stress in cultured human corneal epithelial cells. Cornea 27: 574-579.
5. Debbasch C, De Saint Jean M, Pisella PJ, Rat P, Warnet JM, Baudouin C (1999) Quaternary ammonium cytotoxicity in a human conjunctival cell line. J Fr Ophtalmol 22: 950-958.
6. Dillen K, Bozdag S, Vandervoort J, Ludwig A (2007) Evaluation of the physicochemical characteristics and activity of various kinds of ciprofloxacin HCl-loaded cationic nanoparticles. J Drug Deliv Sci Technol 17: 49-56. (Pubitemid 46347815)
7. Donnenfeld E, Pflugfelder SC (2009) Topical ophthalmic cyclosporine: pharmacology and clinical uses. Surv Ophthalmol 54: 321-338.
8. Garrett Q, Sharon S, Simmons PA, Vehige JG, Willcox M (2010) Carnitine and the potential osmoprotectants protect corneal epithelial cells from hyperosmolar solution induced damage. ARVO Annual meeting Fort Lauderdale.
9. Hermans K, Van den Plas D, Everaert A, Weyenberg W, Ludwig A (2012) Full factorial design, physicochemical characterization and biological assesment of cyclosporine A loaded cationic nanoparticles. Eur J Pharm Biopharm 81: 27-35.
10. Lee VHL, Robinson JR (1986) Topical ocular drug delivery: recent developments and future challenges. J Ocul Pharmacol 2: 67-108. (Pubitemid 17193813)
11. Li M, Rouaud O, Poncelet D (2008) Microencapsulation by solvent evaporation: State of the art for process engineering approaches. Int J Pharm 363: 26-39.
12. LudwigA(2005) The use of mucoadhesive polymers in ocular drug delivery. Adv Drug Del Rev 57: 1595-1639. (Pubitemid 41443472)
13. Matsuo T, Tsuchida Y, Morimoto N (2002) Trehalose eye drops in the treatment of dry eye syndrome. Ophthalmology 109: 2024-2029. (Pubitemid 35222555)
14. Nagarwal RC, Kant S, Singh PN, Maiti P, Pandit JK (2009) Polymeric nanoparticulate system: A potential approach for ocular drug delivery. J Control Release 136: 2-13.
15. Pescosolido N, Imperatrice B, Koverech A, Messano M (2009) L-carnitine and short chain esters in tears from patients with dry eye. Optom Vis Sci 86: 132-138.
16. Pflugfelder SC (2004) Antiinflammatory therapy for dry eye. Am J Ophthalmol 137: 337-342. (Pubitemid 38221009)
17. Sintzel MB, Bernatchez SF, Tabatabay C, Gurny R (1996) Biomaterials in ophthalmic drug delivery. Eur J Pharm Biopharm 42: 358-374. (Pubitemid 27490453)
18. Vandervoort J, Yoncheva K, Ludwig A (2004) Influence of the homogenisation procedure on the physicochemical properties of PLGA nanoparticles. Chem Pharm Bull 52: 1273-1279. (Pubitemid 41364442)
19. Uematsu M, Kumagami T, Shimoda K, Kusano M, Teshima M, Sasaki H, Kitaoka T (2010) Influence of alkyl chain length of benzalkonium chloride on acute corneal epithelial toxicity. Cornea 29: 1296-1301.
20. Waldmeier PC, Zimmermann K, Qian T, Tintelnot-Blomley M, Lemasters JJ (2003) Cyclophilin D as a drug target. Curr Med Chem 10: 1485-1506. (Pubitemid 36896552)
21. Xu S, Flanagan JL, Simmons PA, Vehige J, Willcox MD, Garrett Q (2010) Transport of L-carnitine in human corneal and conjunctival epithelial cells. Mol Vis 16: 1823-1831.
22. Zimmer A, Kreuter J (1995) Microsperes and nanoparticles used in ocular delivery systems. Adv Drug Del Rev 16: 61-73.
23. Kessler H, Loosli HR, Oschkinat H (1985) Assignment of the 1H, 13C, and 15N-NMR spectra of Cyclosporine A in CDCL3 and C6D6 by a combination of homo-and heteronuclear two-dimensional techniques. Helv Chim Acta 68: 661-681. (Pubitemid 15111783)